Sign in
MSLE Stock Price, Chart, Stats & News
Satellos Bioscience Inc.
Save
8.94M
Market cap
–
Current P/E
–
Forward P/E
MSLE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.55% |
ROA | -55.65% |
ROE | -51.76% |
D/E | – |
Interest coverage ratio | – |
MSLE valuation
P/E | – |
P/S | – |
P/B | 2.54x |
P/CF | -4.10x |
P/FCF | -0.38x |
P/OCF | -4.10x |
PEG | -0.18x |
EV multiple | -1.23x |
About
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.
Similar securities
Based on sector and market capitalization
Report issue